Citation Impact
Citing Papers
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
2011 Standout
Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis
2006
Graft microvascular disease in solid organ transplantation
2014 StandoutNobel
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
2021 Standout
Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
2014
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
2015
Interstitial Lung Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases
2014
Drug Treatment of Idiopathic Pulmonary Fibrosis
2016
Lung cancer in patients with idiopathic pulmonary fibrosis
2017
BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo
2005
Idiopathic pulmonary fibrosis
2017 Standout
Fibrosing interstitial lung diseases: knowns and unknowns
2019
Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis
2014
Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies
2017
Signal integration by JNK and p38 MAPK pathways in cancer development
2009 Standout
Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling
2016
Chemical Genetics Define the Roles of p38α and p38β in Acute and Chronic Inflammation
2007
PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake
2018 StandoutNobel
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis
2013
The role of the AU-rich elements of mRNAs in controlling translation
2004
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
2012
TGF-β: the master regulator of fibrosis
2016 Standout
Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy
2004
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
2016
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Mitogen activated protein kinase inhibitors: where are we now and where are we going?
2006
Interleukin 1α (IL-1α) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function
2003
MAPKs and their relevance to arthritis and inflammation
2007
Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease
2009
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
2016
Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2006
Effective clearance of intracellular Leishmania majorin vivo requires Pten in macrophages
2008 StandoutNobel
MAP kinase signalling pathways in cancer
2007 Standout
Asthma
2017 Standout
Cytokines sing the blues: inflammation and the pathogenesis of depression
2005 Standout
Pulmonary fibrosis: patterns and perpetrators
2012
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
2016
Tyrosine kinase signaling in fibrotic disorders
2012
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
2014
Macrophages in Tissue Repair, Regeneration, and Fibrosis
2016 Standout
MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits
2005
Cellular processing of platinum anticancer drugs
2005 Standout
Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase*
2011
Fevipiprant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
2016
Plant Polyphenols as Dietary Antioxidants in Human Health and Disease
2009 Standout
Remodelling the extracellular matrix in development and disease
2014 Standout
Idiopathic pulmonary fibrosis
2017 Standout
Therapeutic targets in idiopathic pulmonary fibrosis
2017
Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
2019 Standout
Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants
2002
Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials
2013
D prostanoid receptor 2 (chemoattractant receptor–homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells
2014
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
2014
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
2014
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
2003
Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
2015
Natural history of idiopathic pulmonary fibrosis
2015
Activation of p38 mitogen‐activated protein kinase in spinal microglia is a critical link in inflammation‐induced spinal pain processing
2003
Potential approaches to reverse or repair renal fibrosis
2014
Itraconazole
1996
Neutrophils in cancer: neutral no more
2016 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
2014
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
2016
Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity
2009 Standout
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
2016
Effects of nintedanib on the microvascular architecture in a lung fibrosis model
2017
Control of translation and mRNA degradation by miRNAs and siRNAs: Table 1.
2006 Standout
Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012
2012
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
2013
The role of inflammation in depression: from evolutionary imperative to modern treatment target
2015 Standout
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
2019
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
2009 Standout
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
2003 Standout
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
2015
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
2015
Wound repair and regeneration: Mechanisms, signaling, and translation
2014 Standout
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019 Standout
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
2009 Standout
Acute and subacute idiopathic interstitial pneumonias
2016
Synthesis of Pyridine and Dihydropyridine Derivatives by Regio- and Stereoselective Addition toN-Activated Pyridines
2012 Standout
Synthesis of a Naphthyridone p38 MAP Kinase Inhibitor
2006
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
2020 Standout
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
2019
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
2003
Therapy for Fibrotic Diseases: Nearing the Starting Line
2013
Current and Emerging Azole Antifungal Agents
1999 Standout
Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy
2004 Standout
The CXC chemokine MIP-2 stimulates neutrophil mobilization from the rat bone marrow in a CD49d-dependent manner
2004
Macrophage glucocorticoid receptors regulate Toll-like receptor 4–mediated inflammatory responses by selective inhibition of p38 MAP kinase
2007
Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand Complexes
2006 Standout
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
2002
Molecular Docking: Shifting Paradigms in Drug Discovery
2019 Standout
Pathogenesis of Idiopathic Pulmonary Fibrosis
2013
Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease
2018
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
2019 Standout
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Large-Scale Applications of Transition Metal-Catalyzed Couplings for the Synthesis of Pharmaceuticals
2011 Standout
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
The selectivity of protein kinase inhibitors: a further update
2007 Standout
Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators
2019
Inflammation and metabolism in tissue repair and regeneration
2017 StandoutScience
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease
2019
p38 MAP kinase inhibitors: A future therapy for inflammatory diseases
2006
Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis
2012
Idiopathic Pulmonary Fibrosis
2018 Standout
PI3K-Akt Pathway Suppresses Coagulation and Inflammation in Endotoxemic Mice
2004
Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation
2015
Macrophage plasticity, polarization, and function in health and disease
2018 Standout
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
Mesenchymal stem cells in the treatment of chronic lung disease
2016
Oxidative damage of SP-D abolishes control of eosinophil extracellular DNA trap formation
2018 StandoutNobel
Works of Abhya Gupta being referenced
P38 Mitogen Activated Protein Kinase Is Involved in the Downregulation of Granulocyte CXC Chemokine Receptors 1 and 2 During Human Endotoxemia
2004
ADVERSE DRUG REACTIONS FROM BIRTH TO EARLY CHILDHOOD
1997
Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis
2013
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
2011
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment
2015
Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia
2003
Safety, pharmacokinetics, and pharmacodynamics of single doses of an oral p38 MAP kinase inhibitor (BIRB 796 BS) in healthy human males a placebo-controlled, randomised study, double blinded at each dose level
2002
Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia
2002
Safety, pharmacokinetics and pharmacodynamics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered once daily for 7 days
2002
Itraconazole in tinea pedis: a dose of 400 mg/day given for 1 week is more effective than 100 or 200 mg/day given for 2-4 weeks
1995